Amgen

Amgen

Biotech company creating biologic medicines

Contract Development Senior Manager - Payer Contracting

Full-TimeUpdated on 9/30/2026
$144.2k - $195.1k/yr

+ Annual bonus + Stock-based long-term incentives

Senior, Expert
Bachelor's, Master's, MBA, PhD, Associate's
Remote in USA
Remote

Must regularly overlap with U.S. Pacific time zone working hours.

About the job

Requirements
  • A doctorate degree and 2 years of sales and marketing operations experience, or a master's degree and 4 years of sales and marketing operations or pricing experience, or a bachelor's degree and 6 years of sales and marketing operations or pricing experience, or an associate's degree and 10 years of sales and marketing operations or pricing experience, or a high school diploma or GED and 12 years of sales and marketing operations or pricing experience.
  • Ability to read and understand complex legal contract documents.
  • Experience managing multiple projects concurrently.
  • Strong negotiation skills.
  • Ability to manage in a highly fluid, interactive, matrixed environment.
  • Deep understanding of the United States commercial and government healthcare and reimbursement environment.
Responsibilities
  • Lead contracting strategy and execution for assigned national payer accounts in alignment with brand and business objectives.
  • Project manage new contracting strategies with major pharmacy benefit managers, collaborating across multiple groups to align on strategies.
  • Co-create the clause library with information technology partners, contract development subject-matter experts, Legal, and Coverage and Pricing.
  • Manage, review, and approve new and updated clauses in Conga and Salesforce.
  • Document and maintain clear guidance for each clause so users can select clauses appropriately.
  • Own the end-to-end contract development process in partnership with Market Access account management, Legal, Coverage and Pricing, and other cross-functional stakeholders.
  • Develop pricing proposals, term sheets, requests for proposal responses, and amendments to support customer negotiations and contract renewals.
  • Serve as the business owner for assigned customer contracts, including contract strategy, negotiation support, execution, and issue escalation.
  • Provide decision-oriented insights to senior leadership on account dynamics, pricing considerations, and contract recommendations.
  • Maintain a strong understanding of assigned customers, including business model, membership trends, financial considerations, market position, and relevant organizational changes.
  • Partner with cross-functional teams to support product-specific pricing strategies and ensure contract terms are operationally executable.
  • Support post-signature contract needs, including contract interpretation, payment-related questions, dispute resolution, formulary validation, and other operational matters.
  • Deliver ad hoc analysis and recommendations related to customer strategy, contract performance, and pricing decisions.
Desired Qualifications
  • An advanced degree, such as a Master of Business Administration, or equivalent experience.
  • Six or more years of experience solving complex business problems.
  • Pharmaceutical or biotechnology sales and marketing experience.
  • A demonstrated track record of increasing responsibility and leadership experience.
  • Previous experience providing and delivering information for executive management decision-making.
  • Previous experience leading a contract development team.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 9% to $10.1 billion, with six growth drugs up 26%.
  • Repatha sales jumped 37% in Q2 2026, and Medicare-access expansion broadens prescriptions.
  • MariTide entered nine Phase 3 studies in 2026, targeting obesity, diabetes, sleep apnea, and cardiovascular disease.

What critics are saying

  • Bristol Myers and Ono sued Amgen on Sept. 15, 2026, over Opdivo biosimilar patents.
  • Britain suspended Tavneos for new patients in September 2026 after calling supporting data unreliable.
  • Prolia and XGEVA biosimilar pressure already cut Q2 2026 sales 33%, and MariTide is unproven.

What makes Amgen unique

  • Amgen’s Aug. 2026 pipeline spans Repatha, IMDELLTRA, MariTide, and olpasiran simultaneously.
  • Repatha holds primary- and secondary-prevention outcomes data, uncommon among PCSK9 competitors.
  • IMDELLTRA became an August 2026 growth engine, reaching $288 million quarterly sales.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.